What is MiMedx Group's market cap?

MiMedx Group (MDXG) has a market capitalization of $634.5M and trades on NASDAQ.

What is MiMedx Group's revenue and profitability?

MiMedx Group generated $355.2M in trailing twelve-month revenue with net income of $6.2M, representing a net margin of 1.8%. Gross margin stands at 78.8%, with free cash flow of $44.5M. These figures are based on the Q2 2026 filing.

Who are MiMedx Group's competitors?

MiMedx Group's key competitors include Organogenesis Holdings Inc., Integra LifeSciences, Solventum Corporation, and others. These companies compete in similar markets and product categories.

Who does MiMedx Group partner with?

MiMedx Group's notable partners include Regenity Biosciences.

Where is MiMedx Group headquartered?

MiMedx Group is headquartered in United States of America and employs approximately 895 people. It has been publicly traded since 2007.

MiMedx Group

MDXG

MiMedx is a biotechnology leader specializing in the development and commercialization of placental biologics and advanced healing solutions.

Market cap

$634.51M-34.1%

Revenue$355.2M-2.4%

Net income$6.2M-80.6%

Free cash flow$44.5M-22.1%

EPS (diluted)$0.04-81.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 29, 2026

Revenue$64.4M EPS-$0.10

Read the full report

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full

Revenue$64.4M-34.7%

Gross profit$44.4M-44.5%

Operating income-$18.5M-249%

Net income-$14.8M-254%

EPS (diluted)-$0.10-267%

Balance sheet

See full

Cash & equivalents$135.8M+14.3%

Total debt$17.2M-6.8%

Total equity$216.0M-0.3%

Total assets$281.0M-3.5%

Cash flow

See full

Operating cash flow-$10.0M-169%

CapEx$598.0K+234%

Free cash flow-$10.6M-175%

Valuation & ratios

Valuation

See full

Market cap$634.51M-34.1%

Enterprise value$515.88M-42.8%

P/E101.7×+70.5×

P/S1.8×-1.0×

Profitability

See full

Gross margin78.8%-2.6pp

Operating margin2.5%-9.3pp

Net margin1.8%-7.1pp

FCF margin12.5%-3.2pp

Returns & leverage

See full

Return on equity2.9%-13.8pp

Debt / equity0.1×0.0×

Current ratio5.3×+0.9×

Segments

By product

See full

Surgical$39.3M+15.1%

Wound$25.1M-61.1%

Competitors

By market cap

Solventum$13.9B+9.2%

IAR

Integra LifeSciences$1.5B+49.2%

MiMedx Group$634.5M-36.7%

Organogenesis Holdings Inc.$328.1M-48.5%

InfuSystem Holdings$188.9M+52.6%

SANUWAVE Health, Inc.$52.5M—

Catheter Precision$1.0M-61.7%

Profusa, Inc. Common Stock$646.6K-99.0%

By revenue growth

SANUWAVE Health, Inc.+22.5%

Organogenesis Holdings Inc.+12.2%

InfuSystem Holdings+3.5%

IAR

Integra LifeSciences+1.6%

Solventum-0.5%

MiMedx Group-2.4%

By net margin

SANUWAVE Health, Inc.37.2%+132pp

Solventum17.33%+12.8pp

InfuSystem Holdings5.56%+3.2pp

MiMedx Group1.76%-7.1pp

Organogenesis Holdings Inc.0.528%+4.0pp

IAR

Integra LifeSciences-0.44%+32.4pp

Profile

MiMedx is a biotechnology leader specializing in the development and commercialization of placental biologics and advanced healing solutions. The company leverages proprietary processing technology to provide a portfolio of human-derived, animal-derived, and synthetic tissues designed to treat chronic wounds, burns, and surgical complications. Their core value proposition centers on reducing healthcare costs and improving patient outcomes through clinically-proven regenerative medicine.

Competitive position

A pioneer in placental biologics with a leading market position in amniotic tissue allografts and a first-mover advantage in the Japanese market.

GeographiesUnited States, Japan

Customer segmentsHealthcare providers, Government health systems, Specialized medical clinics

Business modelDirect sales, Manufacturing and distribution, Licensing and royalties

SuppliersHospital donor networks, Consenting birth tissue donors, Third-party contract manufacturers, Bioresorbable technology developers

CustomersMedicare beneficiaries, Private physician offices, Department of Veterans Affairs, Hospital procurement departments

CountryUnited States of America

Listed2007

Employees895.0

CEOJoseph H. Capper

SectorHealthcare

IndustryBiotechnology

Websitemimedx.com

FilingsSEC EDGAR

Ask your AI about MiMedx Group.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MiMedx Group's market cap?: MiMedx Group (MDXG) has a market capitalization of $634.5M and trades on NASDAQ.
What is MiMedx Group's revenue and profitability?: MiMedx Group generated $355.2M in trailing twelve-month revenue with net income of $6.2M, representing a net margin of 1.8%. Gross margin stands at 78.8%, with free cash flow of $44.5M. These figures are based on the Q2 2026 filing.
Who are MiMedx Group's competitors?: MiMedx Group's key competitors include Organogenesis Holdings Inc., Integra LifeSciences, Solventum Corporation, and others. These companies compete in similar markets and product categories.
Who does MiMedx Group partner with?: MiMedx Group's notable partners include Regenity Biosciences.
Where is MiMedx Group headquartered?: MiMedx Group is headquartered in United States of America and employs approximately 895 people. It has been publicly traded since 2007.